Read by QxMD icon Read

Multiple sclerosis depression

Jason A Berard, Andra M Smith, Lisa A S Walker
Objective: Cognitive fatigue (CF) can be defined as decreased performance with sustained cognitive effort. The present study examined the interrelatedness of disease severity, fatigue, depression, and sleep quality in order to evaluate their predictive roles of CF in MS. Four theoretical models examining these variables were assessed. Methods: Fifty-eight individuals with a diagnosis of MS were recruited. CF was measured by examining last third versus first third performance on the Paced Auditory Serial Addition Test (PASAT)...
February 17, 2018: Archives of Clinical Neuropsychology: the Official Journal of the National Academy of Neuropsychologists
Sarah D Broicher, Linard Filli, Olivia Geisseler, Nicole Germann, Björn Zörner, P Brugger, M Linnebank
OBJECTIVE: To assess the effects of PR-fampridine on cognitive functioning, fatigue and depression in patients with multiple sclerosis (PwMS). METHODS: Thirty-two PwMS were included in this trial. Cognitive performance was assessed in an open-label and randomized double-blind, placebo-controlled study design using a comprehensive neuropsychological test battery as well as questionnaires examining depression and fatigue. RESULTS: We found significant improvements in cognitive measures assessing alertness (tonic alertness, p = 0...
February 20, 2018: Journal of Neurology
U Palm, M A Chalah, A Créange, J-P Lefaucheur, S S Ayache
Fatigue and depression are frequent symptoms in multiple sclerosis (MS). Both are overlapping and shadowing each other and may impair the quality of life. For detection of depression symptoms in MS, the Multiple Sclerosis Depression Rating Scale (MSDRS) has been proposed recently. Here, we compare the performance of MSDRS in MS patients with and without fatigue to that of established rating scales, i.e. Hospital Anxiety and Depression Scale and Beck Depression Inventory. Twenty-nine MS patients were screened for fatigue and depression symptoms...
February 17, 2018: L'Encéphale
L E van den Akker, H Beckerman, E H Collette, H Knoop, G Bleijenberg, J W Twisk, J Dekker, V de Groot
BACKGROUND: Cognitive behavioural therapy (CBT) effectively reduces fatigue directly following treatment in patients with Multiple Sclerosis (MS), but little is known about the process of change during and after CBT. DESIGN: Additional analysis of a randomized clinical trial. OBJECTIVE: To investigate which psychological factors mediate change in fatigue during and after CBT. METHODS: TREFAMS-CBT studied the effectiveness of a 16-week CBT treatment for MS-related fatigue...
March 2018: Journal of Psychosomatic Research
Margaret H Cadden, Peter A Arnett, Tuula M Tyry, Jonathan E Cook
RATIONALE: People living with MS often report feeling stigmatized, but little research has examined the psychological impact of this, which is important considering the high prevalence of depression in this population. OBJECTIVES: The aim of this study was to assess, concurrently and prospectively, the association between stigma and depression in people living with MS. METHODS: Data were available from 5369 participants enrolled in the semi-annual survey conducted by the North American Research Committee on Multiple Sclerosis (NARCOMS)...
February 2, 2018: Social Science & Medicine
Zohara Sternberg
The high prevalence of osteoporosis, observed in multiple sclerosis (MS) patients, has been attributed to reduced mobility and or the use of disease-modifying drugs. However, MS-impaired cardiovascular autonomic nervous system (ANS) function has the potential of reducing bone mass density (BMD) by altering the expression and/or function of the neuronal, systemic, and local mediators of bone remodeling. This review describes the complex regulation of bone homeostasis with a focus on MS, providing evidence that ANS dysfunction and low BMD are intertwined with MS inflammatory and neurodegenerative processes, and with other MS-related morbidities, including depression, fatigue, and migraine...
February 10, 2018: Neuromolecular Medicine
Claudio Solaro, Giulia Gamberini, Fabio Giuseppe Masuccio
Depressive disorders are common in patients with multiple sclerosis, influencing their quality of life and adherence to treatments, as well as becoming more frequent with the progression of the disease and in the secondary progressive form of multiple sclerosis. Patients with multiple sclerosis often experience a typical cluster of symptoms in association with depression, such as fatigue, pain and cognitive impairment. However, the pathogenesis of multiple sclerosis-related depression remains partially unclear, even though genetic, immune-inflammatory and psychosocial factors might be seen to play a role, in addition to the brain structural alterations documented by magnetic resonance imaging studies...
February 7, 2018: CNS Drugs
E Ciampi, R Uribe-San-Martin, M Vásquez, A Ruiz-Tagle, T Labbe, J P Cruz, P Lillo, A Slachevsky, D Reyes, A Reyes, C Cárcamo-Rodríguez
BACKGROUND: Cognitive impairment is a relevant contributor of the medical and social burden in Progressive MS. Social Cognition, the neurocognitive processes underlying social interaction, has been explored mainly in European and North American cohorts, influencing social aspects of quality of life (QOL) of early MS patients and families. Few studies have studied Social Cognition in Progressive MS and the literature on its neuroanatomical bases or brain atrophy measurements is still scarce...
January 25, 2018: Multiple Sclerosis and related Disorders
Stephen P Arnerić, Volker D Kern, Diane T Stephenson
Central Nervous System (CNS) diseases represent one of the most challenging therapeutic areas for successful drug approvals. Developing quantitative biomarkers as Drug Development Tools (DDTs) can catalyze the path to innovative treatments, and improve the chances of drug approvals. Drug development and healthcare management requires sensitive, reliable, validated, and regulatory accepted biomarkers and endpoints. This review highlights the regulatory paths and considerations for developing DDTs required to advance biomarker and endpoint use in clinical development (e...
January 30, 2018: Biochemical Pharmacology
Rina S Fox, Linda Kwakkenbos, Marie-Eve Carrier, Sarah D Mills, Shadi Gholizadeh, Lisa R Jewett, Scott C Roesch, Erin L Merz, Shervin Assassi, Daniel E Furst, Karen Gottesman, Maureen D Mayes, Brett D Thombs, Vanessa L Malcarne
OBJECTIVE: Fear of negative evaluation is a common concern among individuals with visible differences but has received limited attention in systemic sclerosis (SSc), which can involve substantial changes to appearance. The Brief Fear of Negative Evaluation Scale (BFNE) was specifically designed to evaluate fear of negative evaluation. There are currently three versions of the BFNE with strong demonstrated measurement properties: two eight-item versions (BFNE-S, BFNE-8) and one 12-item version (BFNE-II)...
February 6, 2018: Arthritis Care & Research
Laura K Case, Paula Jackson, Revere Kinkel, Paul J Mills
Multiple sclerosis is a disabling and progressive neurological disease that has significant negative effects on health-related quality of life. This exploratory efficacy study examined the effects of Healing Light Guided Imagery (HLGI), a novel variant of guided imagery, compared with a wait-list control in patients with relapsing-remitting multiple sclerosis. Changes in the Beck Depression Inventory, Fatigue Severity Scale, and Multiple Sclerosis Quality of Life instrument (physical and mental components) were compared between groups...
January 2018: J Evid Based Integr Med
S Coe, J Collett, H Izadi, D T Wade, M Clegg, J M Harrison, E Buckingham, A Cavey, G C DeLuca, J Palace, H Dawes
Background: Dietary interventions including consumption of flavonoids, plant compounds found in certain foods, may have the ability to improve fatigue. However, to date, no well-designed intervention studies assessing the role of flavonoid consumption for fatigue management in people with MS (pwMS) have been performed. The hypothesis is that the consumption of a flavonoid-rich pure cocoa beverage will reduce fatigue in pwMS. The aim of this study is to determine the feasibility and potential outcome of running a trial to evaluate this hypothesis...
2018: Pilot and Feasibility Studies
L Lorefice, G Fenu, J Frau, G C Coghe, M G Marrosu, E Cocco
BACKGROUND: Frequently diagnosed in young adulthood, multiple sclerosis (MS) and several MS-related factors can influence patients' unemployment status and negatively affect work productivity and daily functioning. OBJECTIVE: We examined MS patients' employment status and evaluated clinical features influencing it. Furthermore, we investigated patients' burdens due to visible and invisible MS symptoms through their worsening daily functioning. METHODS: The study included outpatients affected by MS according to the 2010 McDonald criteria...
January 31, 2018: Work: a Journal of Prevention, Assessment, and Rehabilitation
Klemens Winder, Ralf A Linker, Frank Seifert, Martina Deutsch, Tobias Engelhorn, Arnd Dörfler, De-Hyung Lee, Katharina M Hösl, Max J Hilz
Erectile function (EF) is frequently compromised in men with multiple sclerosis (MS). Functional neuroimaging in healthy men identified a network of brain areas, such as the insula, visual and somatosensory association areas, cingulate gyrus, prefrontal cortex, as well as subcortical regions, contributing to EF. This study intended to determine associations between EF deterioration during MS and cerebral MS-associated lesion sites. In 31 men with MS (mean age 38.2 ± 11.2 years), we evaluated MS-related EF deterioration by comparing scores of the 5-item International Index of Erectile Function-5 questionnaire (IIEF5) at the time of study and retrospectively, 3 months prior to MS diagnosis, by calculating score differences as DeltaIIEF5 (DeltaIIEF5 score < 0 indicated EF deterioration)...
February 1, 2018: Journal of Neurology
K M S Kanhai, R G J A Zuiker, I Stavrakaki, W Gladdines, P J Gaillard, E S Klaassen, G J Groeneveld
AIM: Intravenous high-dose free methylprednisolone hemisuccinate (MP) is the primary treatment for an acute relapse in relapsing-remitting (RR) multiple sclerosis (MS). However, it is inconvenient and its side effects are undesirable. Both dose and dosing frequency can be reduced by incorporating free MP in glutathione (GSH) PEGylated liposomes, creating a slow-release formulation with reduced toxicity and prolonged peripheral efficacy. This first-in-human study was designed to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of GSH-PEGylated liposomes containing MP (2B3-201)...
January 31, 2018: British Journal of Clinical Pharmacology
Margherita Russo, Vincenzo Dattola, Maria C De Cola, Anna L Logiudice, Bruno Porcari, Antonino Cannavò, Francesca Sciarrone, Rosaria De Luca, Francesco Molonia, Edoardo Sessa, Placido Bramanti, Rocco S Calabrò
Motor impairment is the most common symptom in multiple sclerosis (MS). Thus, a variety of new rehabilitative strategies, including robotic gait training, have been implemented, showing their effectiveness. The aim of our study was to investigate whether an intensive robotic gait training, preceding a traditional rehabilitative treatment, could be useful in improving and potentiating motor performance in MS patients. Forty-five patients, who fulfilled the inclusion criteria, were enrolled in this study and randomized into either the control group (CG) or the experimental group (EG)...
January 30, 2018: International Journal of Rehabilitation Research. Revue Internationale de Recherches de Réadaptation
Jeffrey A Cohen, Samuel F Hunter, Theodore R Brown, Mark Gudesblatt, Ben W Thrower, Lily Llorens, Cindy J Souza-Prien, April E Ruby, David N Chernoff, Rajiv Patni
BACKGROUND: Walking impairment causes disability and reduced quality of life in patients with multiple sclerosis (MS). OBJECTIVE: Characterize the safety and efficacy of ADS-5102 (amantadine) extended release capsules, 274 mg administered once daily at bedtime in patients with MS with walking impairment. METHODS: This randomized, double-blind, placebo-controlled, 4-week study was conducted at 14 trial sites in the United States. Study objectives included safety and tolerability of ADS-5102, and efficacy assessments (Timed 25-Foot Walk (T25FW), Timed Up and Go (TUG), 2-Minute Walk Test, and Multiple Sclerosis Walking Scale-12)...
January 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
Juan J Fernández-Muñoz, Margarita Cigarán-Méndez, Esperanza Navarro-Pardo, Marta Pérez-de-Heredia-Torres, Paula Parás-Bravo, César Fernández-de-Las-Peñas
OBJECTIVES: To determine the mediating effects of depression on health-related quality of life and fatigue in individuals with multiple sclerosis (MS). DESIGN: A cross-sectional study. SETTING: Tertiary urban hospital. PARTICIPANTS: One hundred and eight patients (54% women) with MS participated in this study. OUTCOME MEASURES: Demographic and clinical data (weight, height, medication and neurological impairment), fatigue (Fatigue Impact Scale), depression (Beck Depression Inventory-II) and health-related quality of life (Short-Form Health Survey 36) were collected...
January 23, 2018: BMJ Open
Lorena Lorefice, Giuseppe Fenu, Michela Fois, Jessica Frau, Giancarlo Coghe, Maria Giovanna Marrosu, Eleonora Cocco
BACKGROUND: Several reports suggest a higher risk of psychiatric disorders after high-dose corticosteroids (HDC), routinely used to treat clinical relapses in multiple sclerosis (MS). The present study aimed to examine the possible effect of HDC on mood in patients with MS and to determine the specific factors that influence mood changes. METHODS: The study included MS patients prior to receive HDC. The presence of depressive and bipolar symptoms was determined with the Beck Depression Inventory-Second Edition (BDI-II) and the Mood Disorder Questionnaire (MDQ)...
January 18, 2018: Multiple Sclerosis and related Disorders
Lauren B Strober, Nancy Chiaravalloti, John DeLuca
BACKGROUND: Rates of unemployment among individuals with multiple sclerosis (MS) are as high as 80%. While several factors for such high rates of unemployment have been identified, they do not account for the majority of the variance. OBJECTIVE: This study examines person-specific factors such as personality and coping, which may better account for individuals leaving the workforce. METHOD: Forty individuals with MS (20 considering reducing work hours or leaving the workforce and 20 remaining employed) were matched on age, gender, education, disease duration, and disease course, and administered a comprehensive survey of factors purported to be related to employment status...
January 19, 2018: Work: a Journal of Prevention, Assessment, and Rehabilitation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"